Catherine Offord Overactivation of the brain’s immune cells, called microglia, may play a role in cognitive impairments associated with Down syndrome, according to research published today (October 6) in Neuron. Researchers in Italy identified elevated numbers of the cells in an inflammation-promoting state in the brains of mice with a murine version of the syndrome as well as in postmortem brain tissue from people with the condition. The team additionally showed that drugs that reduce the number of activated microglia in juvenile mice could boost the animals’ performance on cognitive tests. “This is a fabulous study that gives a lot of proof of principle to pursuing some clinical trials in people,” says Elizabeth Head, a neuroscientist at the University of California, Irvine, who was not involved in the work. “The focus on microglial activation, I thought, was very novel and exciting,” she adds, noting that more research will be needed to see how the effects of drugs used in the study might translate from mice to humans. Down syndrome is caused by an extra copy of part or all of human chromosome 21, and is the most commonly occurring chromosomal condition in the US. Children with Down syndrome often experience cognitive delays compared to typically developing children, although there’s substantial variation and the effects are usually mild or moderate. People with the syndrome also have a higher risk of certain medical conditions, including Alzheimer’s disease. © 1986–2020 The Scientist.

Keyword: Development of the Brain; Glia
Link ID: 27537 - Posted: 10.21.2020

By Sundas Hashmi It was the afternoon of Jan. 31. I was preparing for a dinner party and adding final touches to my cheese platter when everything suddenly went dark. I woke up feeling baffled in a hospital bed. My husband filled me in: Apparently, I had suffered a massive seizure a few hours before our guests were to arrive at our Manhattan apartment. Our children’s nanny found me and I was rushed to the hospital. That had been three days earlier. My husband and I were both mystified: I was 37 years old and had always been in excellent health. In due course, a surgeon dropped by and told me I had a glioma, a type of brain tumor. It was relatively huge but operable. I felt sick to my stomach. Two weeks later, I was getting wheeled to the operating theater. I wouldn’t know the pathology until much later. I said my goodbyes to everyone — most importantly to my children, Sofia, 6, and Nyle, 2 — and prepared to die. But right before the surgery, in a very drugged state, I asked the surgeon to please get photos of me and my brother from my husband. I wanted the surgeon to see them. My brother had died two decades earlier from a different kind of brain tumor — a glioblastoma. I was 15 at the time, and he was 18. He died within two years of being diagnosed. Those two years were the worst period of my life. Doctors in my home country of Pakistan refused to take him, saying his case was fatal. So, my parents gathered their savings and flew him to Britain, where he was able to get a biopsy (his tumor was in an inoperable location) and radiation. Afterward, we had to ask people for donations so he could get the gamma knife treatment in Singapore that my parents felt confident would save him. In the end, nothing worked, and he died, taking 18 years of memories with him. © 2020 The New York Times Company

Keyword: Glia
Link ID: 27536 - Posted: 10.21.2020

Shawna Williams In Greek mythology, Orpheus descends to the underworld and persuades Hades to allow him to take his dead wife, Eurydice, back to the realm of the living. Hades agrees, but tells Orpheus that he must not look back until he has exited the underworld. Despite the warning, Orpheus glances behind him on his way out to check whether Eurydice is indeed following him—and loses her forever. The story hints at a dark side to curiosity, a drive to seek certain kinds of knowledge even when doing so is risky—and even if the information serves no practical purpose at the time. In fact, the way people pursue information they’re curious about can resemble the drive to attain more tangible rewards such as food—a parallel that hasn’t been lost on scientists. To investigate the apparent similarity between curiosity and hunger, researchers led by Kou Murayama of the University of Reading in the UK recently devised an experiment to compare how the brain processes desires for food and knowledge, and the risks people are willing to take to satisfy those desires. Beginning in 2016, the team recruited 32 volunteers and instructed them not to eat for at least two hours before coming into the lab. After they arrived, the volunteers’ fingers were hooked up to electrodes that could deliver a weak current, and researchers calibrated the level of electricity to what each participant reported was uncomfortable, but not painful. Then, still hooked up to the electrodes, the volunteers were asked to gamble: they viewed either a photo of a food item or a video of a magician performing a trick, followed by a visual depiction of their odds of “winning” that round (which ranged from 1:6 to 5:6). © 1986–2020 The Scientist.

Keyword: Attention; Obesity
Link ID: 27535 - Posted: 10.21.2020

By Nicholas Bakalar A mother’s psychological distress during pregnancy may increase the risk for asthma in her child, a new study suggests. Researchers had the parents of 4,231 children fill out well-validated questionnaires on psychological stress in the second trimester of pregnancy, and again three years later. The mothers also completed questionnaires at two and six months after giving birth. The study, in the journal Thorax, found that 362 of the mothers and 167 of the fathers had clinically significant psychological distress during the mothers’ pregnancies. When the children were 10 years old, parents reported whether their child had ever been diagnosed with asthma. As an extra measure, the researchers tested the children using forced expiratory volume, or FEV, a standard clinical test of lung function. After controlling for age, smoking during pregnancy, body mass index, a history of asthma and other factors, they found that maternal depression and anxiety during pregnancy was significantly associated with both diagnoses of asthma and poorer lung function in their children. There was no association between childhood asthma and parents’ psychological distress in the years after pregnancy, and no association with paternal psychological stress at any time. “Of course, this could be only one of many causes of asthma,” said the lead author, Dr. Evelien R. van Meel of Erasmus University in Rotterdam, “but we corrected for many confounders, and we saw the effect only in mothers. This seems to suggest that there’s something going on in the uterus. But this is an observational study, and we can’t say that it’s a causal effect.” © 2020 The New York Times Company

Keyword: Depression; Development of the Brain
Link ID: 27534 - Posted: 10.21.2020

By Pam Belluck A potential therapy for amyotrophic lateral sclerosis, a fatal neurological disorder, may allow patients to live several months longer than they otherwise would have, according to a study published Friday. The two-drug combination, dreamed up by two college students, is one of several potential treatments raising the hopes of patients with A.L.S., also known as Lou Gehrig’s disease. The paralytic condition steals people’s ability to walk, speak, eat and ultimately breathe, typically causing death within two to five years. There are only two approved A.L.S. medications, neither tremendously effective. But advocacy efforts by patients and organizations, along with the Ice Bucket Challenge, a highly successful fundraising campaign, have galvanized research into more than 20 therapies that are currently in clinical trials. The two-drug combination, called AMX0035, was conceived seven years ago by Joshua Cohen and Justin Klee, then a junior and senior at Brown University, with the goal of preventing the destruction of neurons that occurs in many brain disorders. It is a combination of an existing supplement and a medication for a pediatric urea disorder. Last month, a study of 137 patients reported that AMX0035 slowed progression of A.L.S. paralysis by about 25 percent more than a placebo. Measuring patients using a scale of physical function, researchers found that those receiving a placebo declined in 18 weeks to a level that patients receiving the treatment didn’t reach until 24 weeks, according to the study’s principal investigator, Dr. Sabrina Paganoni. But because that trial was conducted for only 24 weeks, it left unanswered a crucial question of whether the treatment extended survival for the patients receiving the therapy. After that study ended, 98 of the participants, who had not been told whether they had received placebo or therapy, were given the option of taking the therapy for up to 30 months, a format called an open-label extension study. © 2020 The New York Times Company

Keyword: ALS-Lou Gehrig's Disease
Link ID: 27533 - Posted: 10.19.2020

By Laurie Archbald-Pannone The number of cases of dementia in the United States is rising as baby boomers age, raising questions for boomers themselves and also for their families, caregivers and society. Dementia, which is not technically a disease but a term for impaired ability to think, remember or make decisions, is one of the most feared impairments of old age. Incidence increases dramatically as people move into their 90s. About 5 percent of those 71 to 79 have dementia, and about 37 percent of those about 90 live with it. Older people may worry about their own loss of function as well as the cost and toll of caregiving for someone with dementia. A 2018 study estimated that the lifetime cost of care for a person with Alzheimer’s, the most common form of dementia, to be $329,360. That figure, too, will no doubt rise, putting even more burdens on family, Medicare and Medicaid. There’s also been a good deal of talk and reporting about dementia in recent months because of the presidential election. Some voters have asked whether one or both candidates might have dementia. But is this even a fair question to ask? When these types of questions are posed — adding further stigma to people with dementia — it can unfairly further isolate them and those caring for them. We need to understand dementia and the impact it has on more than 5 million people in the United States who now live with dementia and their caregivers. That number is expected to triple by 2060. First, it is important to know that dementia cannot be diagnosed from afar or by someone who is not a doctor. A person needs a detailed doctor’s exam for a diagnosis. Sometimes, brain imaging is required. And, forgetting an occasional word — or even where you put your keys — does not mean a person has dementia. There are different types of memory loss and they can have different causes, such as other medical conditions, falls or even medication, including herbals, supplements and anything over-the-counter. © 1996-2020 The Washington Post

Keyword: Alzheimers
Link ID: 27532 - Posted: 10.19.2020

By John Horgan One of the most impressive, disturbing works of science journalism I’ve encountered is Anatomy of an Epidemic: Magic Bullets, Psychiatric Drugs, and the Astonishing Rise of Mental Illness in America, published in 2010. In the book, which I review here, award-winning journalist Robert Whitaker presents evidence that medications for mental illness, over time and in the aggregate, cause net harm. In 2012, I brought Whitaker to my school to give a talk, in part to check him out. He struck me as a smart, sensible, meticulous reporter whose in-depth research had led him to startling conclusions. Since then, far from encountering persuasive rebuttals of Whitaker’s thesis, I keep finding corroborations of it. If Whitaker is right, modern psychiatry, together with the pharmaceutical industry, has inflicted iatrogenic harm on millions of people. Reports of surging mental distress during the pandemic have me thinking once again about Whitaker’s views and wondering how they have evolved. Below he answers some questions. —John Horgan
 Horgan: When and why did you start reporting on mental health? Whitaker: It came about in a very roundabout way. In 1994, I had co-founded a publishing company called CenterWatch that covered the business aspects of the “clinical trials industry,” and I soon became interested in writing about how financial interests were corrupting drug trials. Risperdal and Zyprexa had just come to market, and after I used a Freedom of Information request to obtain the FDA’s review of those two drugs, I could see that psychiatric drug trials were a prime example of that corruption. In addition, I had learned of NIMH-funded research that seemed abusive of schizophrenia patients, and in 1998, I co-wrote a series for the Boston Globe on abuses of patients in psychiatric research. My interest was in that broader question of corruption and abuse in research settings, and not specific to psychiatry. © 2020 Scientific American

Keyword: Depression; Schizophrenia
Link ID: 27531 - Posted: 10.19.2020

Moles have a pretty tough life. They live underground, in the dark, burrowing through heavy dirt. And when faced with an enemy, there's nowhere to turn — they have to fight. In most mammals, females tend to be at a disadvantage when it comes to face-to-face combat, because they tend to be smaller and less aggressive than males. But female moles have evolved a secret weapon: a hybrid organ made up of both ovarian and testicular tissue. This effectively makes them intersex, giving them an extra dose of testosterone to make them just as muscular and aggressive as male moles. "As a consequence, basically the whole body of the female, they get masculinized," geneticist Darío Lupiáñez told Quirks & Quarks host Bob McDonald. "They become the body builders of nature." Lupiáñez co-led a study to understand how the moles' genes facilitated this advantage, which was recently published in the journal Science. The research was part of a collaboration between the Max Planck Institute for Molecular Genetics and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association in Germany. Same genes, different instructions The team worked with Iberian moles, commonly found in Spain and Portugal, however this intersex adaptation has been documented in at least six mole species. "We know that intersexuality happens in species like humans, dogs or cats. But the difference actually in moles, it happens all the time, so all the females are intersexual. And this is really something unique among mammals," said Lupiáñez. To understand how moles evolved these intersexual traits, researchers fully mapped the genome of the Iberian mole, commonly found in Spain and Portugal. (David Carmona, Department of Genetics, University of Granada, Spain ) ©2020 CBC/Radio-Canada.

Keyword: Sexual Behavior; Hormones & Behavior
Link ID: 27530 - Posted: 10.19.2020

By Benedict Carey Scott Lilienfeld, an expert in personality disorders who repeatedly disturbed the order in his own field, questioning the science behind many of psychology’s conceits, popular therapies and prized tools, died on Sept. 30 at his home in Atlanta. He was 59. The cause was pancreatic cancer, his wife, Candice Basterfield, said. Dr. Lilienfeld’s career, most of it spent at Emory University in Atlanta, proceeded on two tracks: one that sought to deepen the understanding of so-called psychopathic behavior, the other to expose the many faces of pseudoscience in psychology. Psychopathy is characterized by superficial charm, grandiosity, pathological lying and a lack of empathy. Descriptions of the syndrome were rooted in research in the criminal justice system, where psychopaths often end up. In the early 1990s, Dr. Lilienfeld worked to deepen and clarify the definition. In a series of papers, he anchored a team of psychologists who identified three underlying personality features that psychopaths share, whether they commit illegal acts or not: fearless dominance, meanness and impulsivity. The psychopath does what he or she wants, without anxiety, regret or regard for the suffering of others. “When you have these three systems interacting, it’s a bad brew, and it creates the substrate for what can become psychopathy,” said Mark F. Lenzenweger, a professor of psychology at the State University of New York at Binghamton. “This was Scott’s great contribution: He helped change the thinking about psychopathy, in a profound way, by focusing on aspects of personality, rather than on a list of bad behaviors.” Dr. Lilienfeld’s parallel career encompassed clinical psychology and aimed to shake it free of empty theorizing, softheadedness and bad practice. In the late 1990s and early 2000s, he led a loose group of researchers who began to question the validity of some of the field’s favored constructs, like repressed memories of abuse and multiple personality disorder. The Rorschach inkblot test took a direct hit as largely unreliable. The group also attacked treatments including psychological debriefing and eye movement desensitization and reprocessing, or E.M.D.R., both of which are used for trauma victims. © 2020 The New York Times Company

Keyword: Aggression; Learning & Memory
Link ID: 27529 - Posted: 10.19.2020

By Lydia Denworth, Spectrum, Brendan Borrell, Allyson Berent is a specialty veterinarian in New York City. She treats animals that other doctors cannot help. When no good therapies are available, she invents one. Cats and dogs consumed almost all of her time—until 6 years ago, when her second daughter was born. As a baby, Quincy appeared healthy and happy, smiling at an early age and giggling frequently. But during her first few months of life, she missed many developmental milestones: At 10 weeks, she was not making eye contact. When her parents waved toys in front of her, she stared blankly. She had trouble feeding. And when she was lying on her stomach, she could not lift her head. Doctors kept telling Berent and her husband to give it time, but the couple insisted on genetic testing: At 7 months old, their daughter was diagnosed with Angelman syndrome, a neurodevelopmental condition that affects as many as one in 12,000 people. Most people with Angelman syndrome have severe intellectual disability. They never talk or live an independent life. They experience seizures, gut issues, and sleeping and feeding difficulties. Due to balance and motor problems, they are usually unable or barely able to walk. Many also meet the diagnostic criteria for autism. Within days of learning her daughter’s diagnosis, Berent set herself a new goal: curing Quincy. With her medical background, she had no trouble parsing the scientific research on Angelman syndrome. She learned that it stems from a missing or mutated copy of a gene called UBE3A, which generates a protein essential for healthy brain activity. People inherit two copies of UBE3A, one from each parent, but the paternal copy is typically silent. In about 70% of people with Angelman, the maternal copy is absent, and they produce none of the protein. Many others with the syndrome have a small mutation in the mother’s copy, rendering it ineffective. © 2020 American Association for the Advancement of Science.

Keyword: Autism; Development of the Brain
Link ID: 27528 - Posted: 10.16.2020

Jon Hamilton Researchers appear to have shown how the brain creates two different kinds of thirst. The process involves two types of brain cells, one that responds to a decline in fluid in our bodies, while the other monitors levels of salt and other minerals, a team reports in the journal Nature. Together, these specialized thirst cells seem to determine whether animals and people crave pure water or something like a sports drink, which contains salt and other minerals. "Our brain can detect these two distinct stimuli with different cell types," says Yuki Oka, a professor of biology at Caltech and the study's lead author. The finding appears to help answer "this question that we've been trying to ask for decades and decades and decades," says Sean Stocker, a professor at the University of Pittsburgh who studies water and salt balance in the body. Stocker was not involved in the study. Oka's research is part of an effort to understand the brain biology underlying behavior that's seen in people and many animals. Article continues after sponsor message For example, people who've just finished a long, sweaty workout often experience a special kind of thirst. "Pure water doesn't do it, right? It's not enough," Oka says. "You need water and salt to recover. And we can easily imagine that under such condition, we crave [a] sport drink." Sports drinks like Gatorade generally include a mix of salt and sugar, as well as water. To understand what triggers this type of thirst, Oka's team studied cells in two regions of mouse brains. Both regions are known to contain neurons involved in the sensation of thirst. © 2020 npr

Keyword: Miscellaneous
Link ID: 27527 - Posted: 10.16.2020

by Angie Voyles Askham Autism is a neurodevelopmental condition. Although it is diagnosed based on the presence of two core behaviors — restricted interests and repetitive behaviors, as well as difficulties with social interactions and communication — those traits are thought to arise because of alterations in how different parts of the brain form and connect to one another. No research has uncovered a ‘characteristic’ brain structure for autism, meaning that no single pattern of changes appears in every autistic person. Studies of brain structure often turn up dissimilar results — there is great variety across individuals in general. But some trends have begun to emerge for subsets of autistic people. These differences might one day provide some insight into how some autistic people’s brains function. They may also point to bespoke treatments for particular subtypes of autism. Here is what we know about how brain structure differs between people with and without autism. Which brain regions are known to be structurally different between autistic and non-autistic people? Children and adolescents with autism often have an enlarged hippocampus, the area of the brain responsible for forming and storing memories, several studies suggest, but it is unclear if that difference persists into adolescence and adulthood1,2. © 2020 Simons Foundation

Keyword: Autism
Link ID: 27526 - Posted: 10.16.2020

Frank R. Lin, M.D., Ph.D. When I was going through my otolaryngology residency at Johns Hopkins in the early 2000s, I was struck by the disparity between how hearing loss was managed in children and in older adults. In the case of the child, it was a medical priority to ensure access to a hearing aid so he or she could communicate optimally at home and in school, and such devices were covered by insurance. This approach was justified based on extensive research demonstrating that hearing loss could have a substantial impact on a child’s cognitive and brain development, with lifetime consequences for educational and vocational achievement. For the older adult, the approach was radically different, even if the degree of hearing impairment was the same as in the child. The adult would be reassured that the deficit was to be expected, based on his or her age, and told that a hearing aid, if desired, would represent an out-of-pocket expense averaging about $4,000. Medicare provided no coverage for hearing aids. There was no robust research demonstrating meaningful consequences of hearing loss for older adults, as there was for children, and the clinical approach was typically guided by the notion that it was a very common, and hence inconsequential, aspect of aging. But this approach didn’t make sense, given what I had observed clinically. Older adults with hearing loss recounted to me their sense of isolation and loneliness, and the mental fatigue of constantly concentrating in trying to follow conversations. Family members would often describe a decline in patients’ general well-being and mental acuity as they struggled to hear. For those who obtained effective treatment for their hearing loss with hearing aids or a cochlear implant, the effects were often equally dramatic. Patients spoke of reengaging with family, no longer getting fatigued from straining to listen, and becoming their “old selves” again. If hearing was fundamentally important for children and represented a critical sensory input that could affect brain function, wouldn’t loss of hearing have corresponding implications for the aging brain and its function? © 2020 The Dana Foundation.

Keyword: Hearing; Alzheimers
Link ID: 27525 - Posted: 10.16.2020

By Nicholas Bakalar Weighted blankets, which have long been popular aids to induce calm, could help reduce insomnia, a new study suggests. Swedish researchers studied 121 patients with depression, bipolar disorder and other psychiatric diagnoses, all of whom had sleep problems. They randomly assigned them to two groups. The first slept with an 18-pound blanket weighted with metal chains, and the second with an identical looking three-pound plastic chain blanket. The study, in the Journal of Clinical Sleep Medicine, used the Insomnia Severity Index, a 28-point questionnaire that measures sleep quality, and participants wore activity sensors on their wrists to measure sleep time, awakenings and daytime activity. More than 42 percent of those using the heavy blanket scored low enough on the Insomnia Severity Index to be considered in remission from their sleep troubles, compared with 3.6 percent of the controls. The likelihood of having a 50 percent reduction on the scale was nearly 26 times greater in the weighted blanket group. The weighted blankets did not have a significant effect on total sleep time, but compared with the controls, the users had a significant decrease in wakenings after sleep onset, less daytime sleepiness and fewer symptoms of depression and anxiety. The senior author, Dr. Mats Adler of the Karolinska Institute in Stockholm, acknowledged that this is only one study and doesn’t provide scientific proof that the blankets work. “I have colleagues using it, and they love it,” he said, “but that’s not proof. This study is an indication that they may work, but more studies should be done.” © 2020 The New York Times Company

Keyword: Sleep
Link ID: 27524 - Posted: 10.16.2020

Keith A. Trujillo1, Alfredo Quiñones-Hinojosa2, Kenira J. Thompson3 Joe Louis Martinez Jr. died on 29 August at the age of 76. In addition to making extraordinary contributions to the fields of neurobiology and Chicano psychology, Joe was a tireless advocate of diversity, equity, and inclusion in the sciences. He established professional development programs for individuals from underrepresented groups and provided lifelong mentoring as they pursued careers in science and academia. Joe was passionately devoted to expanding opportunities in the sciences well before diversity became a visible goal for scientific organizations and academic institutions. Born in Albuquerque, New Mexico, on 1 August 1944, Joe received his bachelor's degree in psychology from the University of San Diego in 1966; his master's in experimental psychology from New Mexico Highlands University in 1968; and his Ph.D. in physiological psychology from the University of Delaware in 1971. His faculty career began in 1972 at California State University, San Bernardino (CSUSB), shortly after the campus was established. He later completed postdocs in the laboratory of neurobiologist James McGaugh at the University of California, Irvine, and with neurobiologist Floyd Bloom at the Salk Institute for Biological Studies in San Diego, California. The University of California, Berkeley, recruited Joe in 1982, and he served as a professor as well as the area head of biopsychology and faculty assistant to the vice chancellor for affirmative action. As the highest-ranking Hispanic faculty member in the University of California system, Joe used his voice to help others from underrepresented groups. However, he felt that he could have a greater impact on diversity in the sciences by helping to build a university with a high concentration of Hispanic students, so in 1995 he moved to the University of Texas, San Antonio (UTSA). He began as a professor of biology and went on to assume a range of leadership roles, including director of the Cajal Neuroscience Institute. At UTSA, he worked with colleagues to obtain nearly $18 million in funding for neuroscience research and education. In 2012, he moved to the University of Illinois at Chicago where he served as professor and psychology department head until his retirement in 2016. At each institution, he embraced the opportunity to provide guidance and mentoring to innumerable students, faculty, and staff. © 2020 American Association for the Advancement of Science.

Keyword: Learning & Memory
Link ID: 27523 - Posted: 10.16.2020

By Pam Belluck After contracting the coronavirus in March, Michael Reagan lost all memory of his 12-day vacation in Paris, even though the trip was just a few weeks earlier. Several weeks after Erica Taylor recovered from her Covid-19 symptoms of nausea and cough, she became confused and forgetful, failing to even recognize her own car, the only Toyota Prius in her apartment complex’s parking lot. Lisa Mizelle, a veteran nurse practitioner at an urgent care clinic who fell ill with the virus in July, finds herself forgetting routine treatments and lab tests, and has to ask colleagues about terminology she used to know automatically. “I leave the room and I can’t remember what the patient just said,” she said, adding that if she hadn’t exhausted her medical leave she’d take more time off. “It scares me to think I’m working,” Ms. Mizelle, 53, said. “I feel like I have dementia.” It’s becoming known as Covid brain fog: troubling cognitive symptoms that can include memory loss, confusion, difficulty focusing, dizziness and grasping for everyday words. Increasingly, Covid survivors say brain fog is impairing their ability to work and function normally. “There are thousands of people who have that,” said Dr. Igor Koralnik, chief of neuro-infectious disease at Northwestern Medicine in Chicago, who has already seen hundreds of survivors at a post-Covid clinic he leads. “The impact on the work force that’s affected is going to be significant. Scientists aren’t sure what causes brain fog, which varies widely and affects even people who became only mildly physically ill from Covid-19 and had no previous medical conditions. Leading theories are that it arises when the body’s immune response to the virus doesn’t shut down or from inflammation in blood vessels leading to the brain. © 2020 The New York Times Company

Keyword: Alzheimers; Learning & Memory
Link ID: 27522 - Posted: 10.12.2020

By Eddie Jacobs How would you feel about a new therapy for your chronic pain, which—although far more effective than any available alternative—might also change your religious beliefs? Or a treatment for lymphoma that brings one in three patients into remission, but also made them more likely to vote for your least preferred political party? These seem like idle hypothetical questions about impossible side effects. After all, this is not how medicine works. But a new mental health treatment, set to be licensed next year, poses just this sort of problem. Psychotherapy assisted by psilocybin, the psychedelic compound in “magic mushrooms,” seems to be remarkably effective in treating a wide range of psychopathologies, but also causes a raft of unusual nonclinical changes not seen elsewhere in medicine. Although its precise therapeutic mechanisms remain unclear, clinically relevant doses of psilocybin can induce powerful mystical experiences more commonly associated with extended periods of fasting, prayer or meditation. Arguably, then, it is unsurprising that it can generate long-lasting changes in patients: studies report increased prosociality and aesthetic appreciation, plus robust shifts in personality, values and attitudes to life, even leading some atheists to find God. What’s more, these experiences appear to be a feature, rather than a bug, of psilocybin-assisted psychotherapy, with the intensity of the mystical experience correlating with the extent of clinical benefit. © 2020 Scientific American,

Keyword: Drug Abuse; Emotions
Link ID: 27521 - Posted: 10.12.2020

By Linda Searing U.S. deaths from overdoses of cocaine, a powerfully addictive stimulant, numbered 14,666 in 2018, the most recent year tallied, according to a new report from the Centers for Disease Control and Prevention. The rate of overdose deaths remained stable from 2009 through 2013, the report found, but then headed upward at about 27 percent each year from 2013 through 2018. That rate increase represents about 2½ times more cocaine-related deaths in 2018 than in 2014. Although the report does not address potential causes of the increase in cocaine overdose deaths, the Drug Enforcement Administration has said increased availability of the drug, “in large part due to record levels of coca cultivation and cocaine production in Colombia,” has led to increased usage in the United States. The CDC report says that the rate of overdose deaths from cocaine was higher among men than women and more common among middle-aged people (35 to 44 years old), those living in urban rather than rural areas, and people residing in the Northeast region. In addition, the rate of overdose deaths attributed to cocaine laced with a synthetic opioid such as fentanyl increased faster in recent years than did overdose deaths from purely cocaine. Cocaine overdoses can cause breathing problems, high blood pressure, hallucinations and extreme agitation, as well as seizures, heart attacks and strokes.

Keyword: Drug Abuse
Link ID: 27520 - Posted: 10.12.2020

By Katherine J. Wu Researchers in Iceland have identified a new mutant superpower — but the genetic trait probably won’t be granting anyone admission to the X-Men. A small contingent of the world’s population carries a mutation that makes them immune to the odious funk that wafts off fish, according to a study of some 11,000 people published Thursday in the journal Current Biology. The trait is rare, but potent: When faced with a synthetic odor that would put many people off their lunch, some test subjects smelled only the pleasant aroma of caramel, potato or rose. The vast majority of people aren’t so lucky. Nearly 98 percent of Icelanders, the research said, are probably as put off by the scent as you’d expect. The mutation is thought to be even rarer in populations in other countries. “I can assure you I do not have this mutation,” said Dr. Kári Stefánsson, a neurologist and the study’s senior author. “I tend to get nauseated when I get close to fish that is not completely fresh.” Dr. Stefánsson is the founder and chief executive of deCODE genetics, a biopharmaceutical company in Iceland’s capital, Reykjavik, which has been parsing the human genome for several decades. The team’s latest caper involved a deep dive into the underappreciated sense of olfaction. Study participants were asked to take a whiff of six Sniffin’ Sticks — pens imbued with synthetic odors resembling the recognizable scents of cinnamon, peppermint, banana, licorice, lemon and fish. They were asked to identify the smell, then rate its intensity and pleasantness. The older the study subjects were, the more they struggled to accurately pinpoint the scents. That’s unsurprising, given that sensory functions tend to decline later in life, said Rósa Gísladóttir, the study’s lead author. But even younger people didn’t always hit the mark, she said. The lemon and banana sticks, for instance, prompted descriptions of gummy bears and other candy-sweet smells. © 2020 The New York Times Company

Keyword: Chemical Senses (Smell & Taste); Genes & Behavior
Link ID: 27519 - Posted: 10.10.2020

By Bret Stetka The human brain is hardwired to map our surroundings. This trait is called spatial memory—our ability to remember certain locations and where objects are in relation to one another. New findings published today in Scientific Reports suggest that one major feature of our spatial recall is efficiently locating high-calorie, energy-rich food. The study’s authors believe human spatial memory ensured that our hunter-gatherer ancestors could prioritize the location of reliable nutrition, giving them an evolutionary leg up. In the study, researchers at Wageningen University & Research in the Netherlands observed 512 participants follow a fixed path through a room where either eight food samples or eight food-scented cotton pads were placed in different locations. When they arrived at a sample, the participants would taste the food or smell the cotton and rate how much they liked it. Four of the food samples were high-calorie, including brownies and potato chips, and the other four, including cherry tomatoes and apples, were low in calories—diet foods, you might call them. After the taste test, the participants were asked to identify the location of each sample on a map of the room. They were nearly 30 percent more accurate at mapping the high-calorie samples versus the low-calorie ones, regardless of how much they liked those foods or odors. They were also 243 percent more accurate when presented with actual foods, as opposed to the food scents. “Our main takeaway message is that human minds seem to be designed for efficiently locating high-calorie foods in our environment,” says Rachelle de Vries, a Ph.D. candidate in human nutrition and health at Wageningen University and lead author of the new paper. De Vries feels her team’s findings support the idea that locating valuable caloric resources was an important and regularly occurring problem for early humans weathering the climate shifts of the Pleistocene epoch. “Those with a better memory for where and when high-calorie food resources would be available were likely to have a survival—or fitness—advantage,” she explains. © 2020 Scientific American

Keyword: Learning & Memory; Obesity
Link ID: 27518 - Posted: 10.10.2020